Загрузка...
NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety
A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-α and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Baishideng Publishing Group Inc
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4033290/ https://ncbi.nlm.nih.gov/pubmed/24868326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v6.i5.326 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|